- Investopedia•12 days ago
Rexahn Pharmaceuticals has seen its shares fall sharply over the last month. Can its latest trial data offer optimism for a rally?
- GlobeNewswire•14 days agoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress
RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior Therapies had been Ineffective. Supinoxin™ was Safe and Well Tolerated in Patients with Advanced and Metastatic ...
- Investopedia•17 days ago
Pancreatic cancer is one of the most aggressive diseases in the world. Rexahn Pharmaceuticals offers insight on its latest trials to treat this disease.
Rexahn Pharmaceuticals, Inc. (RNN)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||0.17 x 5000|
|Ask||0.19 x 300|
|Day's Range||0.17 - 0.18|
|52wk Range||0.16 - 0.52|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.65|
|Avg Vol (3m)||921,787|
|Dividend & Yield||N/A (N/A)|